Furthermore, treatment of tumor cells with JSH23 could block tumor migration of the CD3+ T cells induced by the Arf1-CCL5 pathway in CT26 cells (Fig. 5f, Supplementary Fig. S5h). Here, ARF1 is linked to neoplasm.